Gene Therapy Market By Type (Germ Line Gene Therapy, Somatic Gene Therapy {Ex Vivo Gene Therapy, In Vivo Gene Therapy), By Therapy Area (Cancer, Infectious Diseases, Rheumatoid Arthritis, Genetic Disorders, Neurological Disorders, Others), By Vector Type (Viral Vectors {Adenoviruses, Retroviruses, Alphaviruses, Adeno-Associated Virus, Herpes Simplex Virus, Vaccinia Viruses, Others}, Non- Viral Vectors {Naked DNA, Oligonucleotides, Lipoplexes and Polyplexes}, Human Artificial Chromosome) By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027
Industry Trends
Global gene therapy market was valued at US$ 919.6 million in 2018 and is expected to reach US$ 5,609.9 million by 2027, growing at an estimated CAGR of 8.2% over the forecast period. The introduction of gene with the potential to cure or prevent the growth of a disease is termed as Gene Therapy. Increasing investment in research and development to discover lifesaving treatment for advanced diseases such as Cancer is driving the overall gene therapy market.
Gene therapy market is growing at a notable pace. Genetic or hereditary defects such as cardiovascular diseases, neurological disorders amongst others can be cured using gene therapy by introducing functional gene in the body and eliminating the defective ones. Gene therapy is categorized into somatic cell gene therapy and reproductive or germ line gene therapy. Gene therapy of Somatic cell are related to cells other than the germ cells or the reproductive cells while the germ line therapy are related to the reproductive cells with an objective to make changes to the hereditary factors to get the desired offspring. Somatic gene therapy can be further bifurcated into ex vivo gene therapy and in vivo gene therapy. In ex vivo gene therapy the cells are altered outside the body and the planted into the body while in the in vivo therapy cells are dealt inside the body. Somatic cell gene therapy is currently focusing on the treatment of tissue restricted disease such as Cystic Fibrosis, Adenosine Deaminase.
If a family has genetic disease like Hemophilia it can only be treated through Germ line therapy which involves modification of the genes inside sperm or egg cells, so that offspring will have the modified genes and will not be affected with genetic disease the family is carrying since ages. The functional copy of the gene is integrated into the reproductive cells suing vectors. The viruses are good vectors as they are designed to invade cells and introduce their DNA. The viruses are designed to introduce the foreign DNA to the target cells.
North America is expected to hold the largest market share in the gene therapy market over the next eight years owing to large scale investments in research and development to meet the rising need of acute disease treatment. Rise in government investments to develop cure for lethal diseases and approval and commercialization of such therapeutic products is boosting the market.
Global Gene Therapy Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of gene therapy market, as well as provides comprehensive insights and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major Gene Therapy Market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, specification, pricing, and gross margin.
Some of the players operating in the gene therapy market are Voyager Therapeutics, Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Human Stem Cells Institute PJSC, Orchard Therapeutics plc, Genenta Science, Chiesi Farmaceutici S.p.A., Novartis AG, GlaxoSmithKline PLC, Gilead Sciences, Inc., Bristol - Myers Squibb Delta Company Limited, Advanced Cell & Gene Therapy, LLC, Audentes Therapeutics, Inc., Biogen, and Pfizer Inc. amongst others.
Gene Therapy Market:
- By Type
- Germ Line Gene Therapy
- Somatic Gene Therapy
- Ex Vivo Gene Therapy
- In Vivo Gene Therapy
- By Therapy Area:
- Cancer
- Infectious Diseases
- Rheumatoid Arthritis
- Genetic Disorders
- Neurological Disorders
- Others
- By Vector Type:
- Viral Vectors
- Adenoviruses
- Retroviruses
- Alphaviruses
- Adeno- Associated Virus
- Herpes Simplex Virus
- Vaccinia Viruses
- Others (Lentivirus, Vaccinia Virus, Etc.)
- Non-Viral Vectors
- Naked DNA
- Oligonucleotides
- Lipoplexes and Polyplexes
- Human Artificial Chromosome
- Viral Vectors
- By Geography
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Gene Therapy Market
6. Market Synopsis: Gene
Therapy Market
7. Gene Therapy Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in
Gene Therapy Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Gene Therapy Market
7.6. Porter’s
Five Force Analysis
8. Global Gene Therapy Market Analysis and Forecasts, 2019 –
2027
8.1. Overview
8.1.1. Global
Gene Therapy Market Revenue (US$ Mn)
8.2. Global
Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Germ
Line Gene Therapy
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2013 – 2018
8.2.1.3. Market Forecast, 2019 – 2027
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Somatic
Gene Therapy (Definition, Market Estimation and Penetration, 2013 – 2018,
Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual
Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific,
Middle East and Africa, Latin America) and Information on Ex Vivo Gene Therapy,
In Vivo Gene Therapy)
8.2.2.1. Ex Vivo Gene Therapy
8.2.2.2. In Vivo Gene Therapy
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Gene Therapy Market Analysis and Forecasts, 2019 –
2027
9.1. Overview
9.2. Global
Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy Area
9.2.1. Cancer
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2013 – 2018
9.2.1.3. Market Forecast, 2019 – 2027
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Infectious
Diseases
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2013 – 2018
9.2.2.3. Market Forecast, 2019 – 2027
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2013 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2013 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2013 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2013 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2013 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.2.3. Rheumatoid
Arthritis
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2013 – 2018
9.2.3.3. Market Forecast, 2019 – 2027
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2013 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2013 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.2.4. Genetic
Disorders
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2013 – 2018
9.2.4.3. Market Forecast, 2019 – 2027
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2013 – 2018
9.2.4.5.1.2. Market
Forecast, 2019 – 2027
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2013 – 2018
9.2.4.5.2.2. Market
Forecast, 2019 – 2027
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2013 – 2018
9.2.4.5.3.2. Market
Forecast, 2019 – 2027
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2013 – 2018
9.2.4.5.4.2. Market
Forecast, 2019 – 2027
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2013 – 2018
9.2.4.5.5.2. Market
Forecast, 2019 – 2027
9.2.5. Neurological
Disorders
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2013 – 2018
9.2.5.3. Market Forecast, 2019 – 2027
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2013 – 2018
9.2.5.5.1.2. Market
Forecast, 2019 – 2027
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2013 – 2018
9.2.5.5.2.2. Market
Forecast, 2019 – 2027
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2013 – 2018
9.2.5.5.3.2. Market
Forecast, 2019 – 2027
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2013 – 2018
9.2.5.5.4.2. Market
Forecast, 2019 – 2027
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2013 – 2018
9.2.5.5.5.2. Market
Forecast, 2019 – 2027
9.2.6. Others
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2013 – 2018
9.2.6.3. Market Forecast, 2019 – 2027
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market
Estimation, 2013 – 2018
9.2.6.5.1.2. Market
Forecast, 2019 – 2027
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2013 – 2018
9.2.6.5.2.2. Market
Forecast, 2019 – 2027
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market
Estimation, 2013 – 2018
9.2.6.5.3.2. Market
Forecast, 2019 – 2027
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market
Estimation, 2013 – 2018
9.2.6.5.4.2. Market
Forecast, 2019 – 2027
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market
Estimation, 2013 – 2018
9.2.6.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Therapy Area
10. Global Gene Therapy Market Analysis and Forecasts, 2019 –
2027
10.1. Overview
10.2. Global
Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Vector Type
10.2.1. Viral
Vectors (Definition, Market Estimation and Penetration, 2013 – 2018, Market
Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Adenoviruses, Retroviruses,
Alphaviruses, Adeno- Associated Virus, Herpes Simplex Virus, Vaccinia Viruses,
Others (Lentivirus, Vaccinia Virus, Etc.))
10.2.1.1. Adenoviruses
10.2.1.2. Retroviruses
10.2.1.3. Alphaviruses
10.2.1.4. Adeno- Associated Virus
10.2.1.5. Herpes Simplex Virus
10.2.1.6. Vaccinia Viruses
10.2.1.7. Others (Lentivirus, Vaccinia Virus, Etc.)
10.2.2. Non-Viral
Vectors (Definition, Market Estimation and Penetration, 2013 – 2018, Market
Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Naked DNA, Oligonucleotides,
Lipoplexes and Polyplexes)
10.2.2.1. Naked DNA
10.2.2.2. Oligonucleotides
10.2.2.3. Lipoplexes and Polyplexes
10.2.3. Human
Artificial Chromosome
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2013 – 2018
10.2.3.3. Market Forecast, 2019 – 2027
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2013 – 2018
10.2.3.5.1.2. Market
Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2013 – 2018
10.2.3.5.2.2. Market
Forecast, 2019 – 2027
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2013 – 2018
10.2.3.5.3.2. Market
Forecast, 2019 – 2027
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2013 – 2018
10.2.3.5.4.2. Market
Forecast, 2019 – 2027
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2013 – 2018
10.2.3.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By
Vector Type
11. North America Gene Therapy Market Analysis and Forecasts,
2019 - 2027
11.1. Overview
11.1.1. North
America Gene Therapy Market Revenue (US$ Mn)
11.2. North
America Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Type
11.2.1. Germ
Line Gene Therapy
11.2.2. Somatic
Gene Therapy
11.2.2.1. Ex Vivo Gene Therapy
11.2.2.2. In Vivo Gene Therapy
11.3. North
America Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy Area
11.3.1. Cancer
11.3.2. Infectious
Diseases
11.3.3. Rheumatoid
Arthritis
11.3.4. Genetic
Disorders
11.3.5. Neurological
Disorders
11.3.6. Others
11.4. North
America Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Vector Type
11.4.1. Viral
Vectors
11.4.1.1. Adenoviruses
11.4.1.2. Retroviruses
11.4.1.3. Alphaviruses
11.4.1.4. Adeno- Associated Virus
11.4.1.5. Herpes Simplex Virus
11.4.1.6. Vaccinia Viruses
11.4.1.7. Others (Lentivirus, Vaccinia Virus, Etc.)
11.4.2. Non-Viral
Vectors
11.4.2.1. Naked DNA
11.4.2.2. Oligonucleotides
11.4.2.3. Lipoplexes and Polyplexes
11.4.3. Human
Artificial Chromosome
11.5. North
America Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.1.1.1. Germ Line Gene Therapy
11.5.1.1.2. Somatic Gene Therapy
11.5.1.1.2.1. Ex
Vivo Gene Therapy
11.5.1.1.2.2. In
Vivo Gene Therapy
11.5.1.2. U.S Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
11.5.1.2.1. Cancer
11.5.1.2.2. Infectious Diseases
11.5.1.2.3. Rheumatoid Arthritis
11.5.1.2.4. Genetic Disorders
11.5.1.2.5. Neurological Disorders
11.5.1.2.6. Others
11.5.1.3. U.S Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
11.5.1.3.1. Viral Vectors
11.5.1.3.1.1. Adenoviruses
11.5.1.3.1.2. Retroviruses
11.5.1.3.1.3. Alphaviruses
11.5.1.3.1.4. Adeno-
Associated Virus
11.5.1.3.1.5. Herpes
Simplex Virus
11.5.1.3.1.6. Vaccinia
Viruses
11.5.1.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
11.5.1.3.2. Non-Viral Vectors
11.5.1.3.2.1. Naked
DNA
11.5.1.3.2.2. Oligonucleotides
11.5.1.3.2.3. Lipoplexes
and Polyplexes
11.5.1.3.3. Human Artificial Chromosome
11.5.2. Canada
11.5.2.1. Canada Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.2.1.1. Germ Line Gene Therapy
11.5.2.1.2. Somatic Gene Therapy
11.5.2.1.2.1. Ex
Vivo Gene Therapy
11.5.2.1.2.2. In
Vivo Gene Therapy
11.5.2.2. Canada Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
11.5.2.2.1. Cancer
11.5.2.2.2. Infectious Diseases
11.5.2.2.3. Rheumatoid Arthritis
11.5.2.2.4. Genetic Disorders
11.5.2.2.5. Neurological Disorders
11.5.2.2.6. Others
11.5.2.3. Canada Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
11.5.2.3.1. Viral Vectors
11.5.2.3.1.1. Adenoviruses
11.5.2.3.1.2. Retroviruses
11.5.2.3.1.3. Alphaviruses
11.5.2.3.1.4. Adeno-
Associated Virus
11.5.2.3.1.5. Herpes
Simplex Virus
11.5.2.3.1.6. Vaccinia
Viruses
11.5.2.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
11.5.2.3.2. Non-Viral Vectors
11.5.2.3.2.1. Naked
DNA
11.5.2.3.2.2. Oligonucleotides
11.5.2.3.2.3. Lipoplexes
and Polyplexes
11.5.2.3.3. Human Artificial Chromosome
11.5.3. Mexico
11.5.3.1. Mexico Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.3.1.1. Germ Line Gene Therapy
11.5.3.1.2. Somatic Gene Therapy
11.5.3.1.2.1. Ex
Vivo Gene Therapy
11.5.3.1.2.2. In
Vivo Gene Therapy
11.5.3.2. Mexico Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
11.5.3.2.1. Cancer
11.5.3.2.2. Infectious Diseases
11.5.3.2.3. Rheumatoid Arthritis
11.5.3.2.4. Genetic Disorders
11.5.3.2.5. Neurological Disorders
11.5.3.2.6. Others
11.5.3.3. Mexico Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
11.5.3.3.1. Viral Vectors
11.5.3.3.1.1. Adenoviruses
11.5.3.3.1.2. Retroviruses
11.5.3.3.1.3. Alphaviruses
11.5.3.3.1.4. Adeno-
Associated Virus
11.5.3.3.1.5. Herpes
Simplex Virus
11.5.3.3.1.6. Vaccinia
Viruses
11.5.3.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
11.5.3.3.2. Non-Viral Vectors
11.5.3.3.2.1. Naked
DNA
11.5.3.3.2.2. Oligonucleotides
11.5.3.3.2.3. Lipoplexes
and Polyplexes
11.5.3.3.3. Human Artificial Chromosome
11.5.4. Rest of
North America
11.5.4.1. Rest of North America Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Type
11.5.4.1.1. Germ Line Gene Therapy
11.5.4.1.2. Somatic Gene Therapy
11.5.4.1.2.1. Ex
Vivo Gene Therapy
11.5.4.1.2.2. In
Vivo Gene Therapy
11.5.4.2. Rest of North America Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Area
11.5.4.2.1. Cancer
11.5.4.2.2. Infectious Diseases
11.5.4.2.3. Rheumatoid Arthritis
11.5.4.2.4. Genetic Disorders
11.5.4.2.5. Neurological Disorders
11.5.4.2.6. Others
11.5.4.3. Rest of North America Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Vector Type
11.5.4.3.1. Viral Vectors
11.5.4.3.1.1. Adenoviruses
11.5.4.3.1.2. Retroviruses
11.5.4.3.1.3. Alphaviruses
11.5.4.3.1.4. Adeno-
Associated Virus
11.5.4.3.1.5. Herpes
Simplex Virus
11.5.4.3.1.6. Vaccinia
Viruses
11.5.4.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
11.5.4.3.2. Non-Viral Vectors
11.5.4.3.2.1. Naked
DNA
11.5.4.3.2.2. Oligonucleotides
11.5.4.3.2.3. Lipoplexes
and Polyplexes
11.5.4.3.3. Human Artificial Chromosome
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By Type
11.6.3. By
Therapy Area
11.6.4. By
Vector Type
12. Europe Gene Therapy Market Analysis and Forecasts, 2019 -
2027
12.1. Overview
12.1.1. Europe
Gene Therapy Market Revenue (US$ Mn)
12.2. Europe
Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Germ
Line Gene Therapy
12.2.2. Somatic
Gene Therapy
12.2.2.1. Ex Vivo Gene Therapy
12.2.2.2. In Vivo Gene Therapy
12.3. Europe
Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy Area
12.3.1. Cancer
12.3.2. Infectious
Diseases
12.3.3. Rheumatoid
Arthritis
12.3.4. Genetic
Disorders
12.3.5. Neurological
Disorders
12.3.6. Others
12.4. Europe
Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Vector Type
12.4.1. Viral
Vectors
12.4.1.1. Adenoviruses
12.4.1.2. Retroviruses
12.4.1.3. Alphaviruses
12.4.1.4. Adeno- Associated Virus
12.4.1.5. Herpes Simplex Virus
12.4.1.6. Vaccinia Viruses
12.4.1.7. Others (Lentivirus, Vaccinia Virus, Etc.)
12.4.2. Non-Viral
Vectors
12.4.2.1. Naked DNA
12.4.2.2. Oligonucleotides
12.4.2.3. Lipoplexes and Polyplexes
12.4.3. Human
Artificial Chromosome
12.5. Europe
Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.1.1.1. Germ Line Gene Therapy
12.5.1.1.2. Somatic Gene Therapy
12.5.1.1.2.1. Ex
Vivo Gene Therapy
12.5.1.1.2.2. In
Vivo Gene Therapy
12.5.1.2. France Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
12.5.1.2.1. Cancer
12.5.1.2.2. Infectious Diseases
12.5.1.2.3. Rheumatoid Arthritis
12.5.1.2.4. Genetic Disorders
12.5.1.2.5. Neurological Disorders
12.5.1.2.6. Others
12.5.1.3. France Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
12.5.1.3.1. Viral Vectors
12.5.1.3.1.1. Adenoviruses
12.5.1.3.1.2. Retroviruses
12.5.1.3.1.3. Alphaviruses
12.5.1.3.1.4. Adeno-
Associated Virus
12.5.1.3.1.5. Herpes
Simplex Virus
12.5.1.3.1.6. Vaccinia
Viruses
12.5.1.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
12.5.1.3.2. Non-Viral Vectors
12.5.1.3.2.1. Naked
DNA
12.5.1.3.2.2. Oligonucleotides
12.5.1.3.2.3. Lipoplexes
and Polyplexes
12.5.1.3.3. Human Artificial Chromosome
12.5.2. The UK
12.5.2.1. The UK Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.2.1.1. Germ Line Gene Therapy
12.5.2.1.2. Somatic Gene Therapy
12.5.2.1.2.1. Ex
Vivo Gene Therapy
12.5.2.1.2.2. In
Vivo Gene Therapy
12.5.2.2. The UK Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
12.5.2.2.1. Cancer
12.5.2.2.2. Infectious Diseases
12.5.2.2.3. Rheumatoid Arthritis
12.5.2.2.4. Genetic Disorders
12.5.2.2.5. Neurological Disorders
12.5.2.2.6. Others
12.5.2.3. The UK Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
12.5.2.3.1. Viral Vectors
12.5.2.3.1.1. Adenoviruses
12.5.2.3.1.2. Retroviruses
12.5.2.3.1.3. Alphaviruses
12.5.2.3.1.4. Adeno-
Associated Virus
12.5.2.3.1.5. Herpes
Simplex Virus
12.5.2.3.1.6. Vaccinia
Viruses
12.5.2.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
12.5.2.3.2. Non-Viral Vectors
12.5.2.3.2.1. Naked
DNA
12.5.2.3.2.2. Oligonucleotides
12.5.2.3.2.3. Lipoplexes
and Polyplexes
12.5.2.3.3. Human Artificial Chromosome
12.5.3. Spain
12.5.3.1. Spain Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.3.1.1. Germ Line Gene Therapy
12.5.3.1.2. Somatic Gene Therapy
12.5.3.1.2.1. Ex
Vivo Gene Therapy
12.5.3.1.2.2. In
Vivo Gene Therapy
12.5.3.2. Spain Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
12.5.3.2.1. Cancer
12.5.3.2.2. Infectious Diseases
12.5.3.2.3. Rheumatoid Arthritis
12.5.3.2.4. Genetic Disorders
12.5.3.2.5. Neurological Disorders
12.5.3.2.6. Others
12.5.3.3. Spain Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
12.5.3.3.1. Viral Vectors
12.5.3.3.1.1. Adenoviruses
12.5.3.3.1.2. Retroviruses
12.5.3.3.1.3. Alphaviruses
12.5.3.3.1.4. Adeno-
Associated Virus
12.5.3.3.1.5. Herpes
Simplex Virus
12.5.3.3.1.6. Vaccinia
Viruses
12.5.3.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
12.5.3.3.2. Non-Viral Vectors
12.5.3.3.2.1. Naked
DNA
12.5.3.3.2.2. Oligonucleotides
12.5.3.3.2.3. Lipoplexes
and Polyplexes
12.5.3.3.3. Human Artificial Chromosome
12.5.4. Germany
12.5.4.1. Germany Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.4.1.1. Germ Line Gene Therapy
12.5.4.1.2. Somatic Gene Therapy
12.5.4.1.2.1. Ex
Vivo Gene Therapy
12.5.4.1.2.2. In
Vivo Gene Therapy
12.5.4.2. Germany Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
12.5.4.2.1. Cancer
12.5.4.2.2. Infectious Diseases
12.5.4.2.3. Rheumatoid Arthritis
12.5.4.2.4. Genetic Disorders
12.5.4.2.5. Neurological Disorders
12.5.4.2.6. Others
12.5.4.3. Germany Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
12.5.4.3.1. Viral Vectors
12.5.4.3.1.1. Adenoviruses
12.5.4.3.1.2. Retroviruses
12.5.4.3.1.3. Alphaviruses
12.5.4.3.1.4. Adeno-
Associated Virus
12.5.4.3.1.5. Herpes
Simplex Virus
12.5.4.3.1.6. Vaccinia
Viruses
12.5.4.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
12.5.4.3.2. Non-Viral Vectors
12.5.4.3.2.1. Naked
DNA
12.5.4.3.2.2. Oligonucleotides
12.5.4.3.2.3. Lipoplexes
and Polyplexes
12.5.4.3.3. Human Artificial Chromosome
12.5.5. Italy
12.5.5.1. Italy Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.5.1.1. Germ Line Gene Therapy
12.5.5.1.2. Somatic Gene Therapy
12.5.5.1.2.1. Ex
Vivo Gene Therapy
12.5.5.1.2.2. In
Vivo Gene Therapy
12.5.5.2. Italy Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
12.5.5.2.1. Cancer
12.5.5.2.2. Infectious Diseases
12.5.5.2.3. Rheumatoid Arthritis
12.5.5.2.4. Genetic Disorders
12.5.5.2.5. Neurological Disorders
12.5.5.2.6. Others
12.5.5.3. Italy Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
12.5.5.3.1. Viral Vectors
12.5.5.3.1.1. Adenoviruses
12.5.5.3.1.2. Retroviruses
12.5.5.3.1.3. Alphaviruses
12.5.5.3.1.4. Adeno-
Associated Virus
12.5.5.3.1.5. Herpes
Simplex Virus
12.5.5.3.1.6. Vaccinia
Viruses
12.5.5.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
12.5.5.3.2. Non-Viral Vectors
12.5.5.3.2.1. Naked
DNA
12.5.5.3.2.2. Oligonucleotides
12.5.5.3.2.3. Lipoplexes
and Polyplexes
12.5.5.3.3. Human Artificial Chromosome
12.5.6. Nordic
Countries
12.5.6.1. Nordic Countries Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.6.1.1. Germ Line Gene Therapy
12.5.6.1.2. Somatic Gene Therapy
12.5.6.1.2.1. Ex
Vivo Gene Therapy
12.5.6.1.2.2. In
Vivo Gene Therapy
12.5.6.2. Nordic Countries Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Area
12.5.6.2.1. Cancer
12.5.6.2.2. Infectious Diseases
12.5.6.2.3. Rheumatoid Arthritis
12.5.6.2.4. Genetic Disorders
12.5.6.2.5. Neurological Disorders
12.5.6.2.6. Others
12.5.6.3. Nordic Countries Gene Therapy Market Revenue (US$ Mn) and Forecasts,
By Vector Type
12.5.6.3.1. Viral Vectors
12.5.6.3.1.1. Adenoviruses
12.5.6.3.1.2. Retroviruses
12.5.6.3.1.3. Alphaviruses
12.5.6.3.1.4. Adeno-
Associated Virus
12.5.6.3.1.5. Herpes
Simplex Virus
12.5.6.3.1.6. Vaccinia
Viruses
12.5.6.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
12.5.6.3.2. Non-Viral Vectors
12.5.6.3.2.1. Naked
DNA
12.5.6.3.2.2. Oligonucleotides
12.5.6.3.2.3. Lipoplexes
and Polyplexes
12.5.6.3.3. Human Artificial Chromosome
12.5.6.4. Nordic Countries Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux Union Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.7.1.1. Germ Line Gene Therapy
12.5.7.1.2. Somatic Gene Therapy
12.5.7.1.2.1. Ex
Vivo Gene Therapy
12.5.7.1.2.2. In
Vivo Gene Therapy
12.5.7.2. Benelux Union Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Area
12.5.7.2.1. Cancer
12.5.7.2.2. Infectious Diseases
12.5.7.2.3. Rheumatoid Arthritis
12.5.7.2.4. Genetic Disorders
12.5.7.2.5. Neurological Disorders
12.5.7.2.6. Others
12.5.7.3. Benelux Union Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Vector Type
12.5.7.3.1. Viral Vectors
12.5.7.3.1.1. Adenoviruses
12.5.7.3.1.2. Retroviruses
12.5.7.3.1.3. Alphaviruses
12.5.7.3.1.4. Adeno-
Associated Virus
12.5.7.3.1.5. Herpes
Simplex Virus
12.5.7.3.1.6. Vaccinia
Viruses
12.5.7.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
12.5.7.3.2. Non-Viral Vectors
12.5.7.3.2.1. Naked
DNA
12.5.7.3.2.2. Oligonucleotides
12.5.7.3.2.3. Lipoplexes
and Polyplexes
12.5.7.3.3. Human Artificial Chromosome
12.5.7.4. Benelux Union Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest of Europe Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.8.1.1. Germ Line Gene Therapy
12.5.8.1.2. Somatic Gene Therapy
12.5.8.1.2.1. Ex
Vivo Gene Therapy
12.5.8.1.2.2. In
Vivo Gene Therapy
12.5.8.2. Rest of Europe Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Area
12.5.8.2.1. Cancer
12.5.8.2.2. Infectious Diseases
12.5.8.2.3. Rheumatoid Arthritis
12.5.8.2.4. Genetic Disorders
12.5.8.2.5. Neurological Disorders
12.5.8.2.6. Others
12.5.8.3. Rest of Europe Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Vector Type
12.5.8.3.1. Viral Vectors
12.5.8.3.1.1. Adenoviruses
12.5.8.3.1.2. Retroviruses
12.5.8.3.1.3. Alphaviruses
12.5.8.3.1.4. Adeno-
Associated Virus
12.5.8.3.1.5. Herpes
Simplex Virus
12.5.8.3.1.6. Vaccinia
Viruses
12.5.8.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
12.5.8.3.2. Non-Viral Vectors
12.5.8.3.2.1. Naked
DNA
12.5.8.3.2.2. Oligonucleotides
12.5.8.3.2.3. Lipoplexes
and Polyplexes
12.5.8.3.3. Human Artificial Chromosome
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By Type
12.6.3. By
Therapy Area
12.6.4. By
Vector Type
13. Asia Pacific Gene Therapy Market Analysis and Forecasts, 2019
- 2027
13.1. Overview
13.1.1. Asia
Pacific Gene Therapy Market Revenue (US$ Mn)
13.2. Asia
Pacific Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Germ
Line Gene Therapy
13.2.2. Somatic
Gene Therapy
13.2.2.1. Ex Vivo Gene Therapy
13.2.2.2. In Vivo Gene Therapy
13.3. Asia
Pacific Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy Area
13.3.1. Cancer
13.3.2. Infectious
Diseases
13.3.3. Rheumatoid
Arthritis
13.3.4. Genetic
Disorders
13.3.5. Neurological
Disorders
13.3.6. Others
13.4. Asia
Pacific Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Vector Type
13.4.1. Viral
Vectors
13.4.1.1. Adenoviruses
13.4.1.2. Retroviruses
13.4.1.3. Alphaviruses
13.4.1.4. Adeno- Associated Virus
13.4.1.5. Herpes Simplex Virus
13.4.1.6. Vaccinia Viruses
13.4.1.7. Others (Lentivirus, Vaccinia Virus, Etc.)
13.4.2. Non-Viral
Vectors
13.4.2.1. Naked DNA
13.4.2.2. Oligonucleotides
13.4.2.3. Lipoplexes and Polyplexes
13.4.3. Human
Artificial Chromosome
13.5. Asia
Pacific Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.1.1.1. Germ Line Gene Therapy
13.5.1.1.2. Somatic Gene Therapy
13.5.1.1.2.1. Ex
Vivo Gene Therapy
13.5.1.1.2.2. In
Vivo Gene Therapy
13.5.1.2. China Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
13.5.1.2.1. Cancer
13.5.1.2.2. Infectious Diseases
13.5.1.2.3. Rheumatoid Arthritis
13.5.1.2.4. Genetic Disorders
13.5.1.2.5. Neurological Disorders
13.5.1.2.6. Others
13.5.1.3. China Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
13.5.1.3.1. Viral Vectors
13.5.1.3.1.1. Adenoviruses
13.5.1.3.1.2. Retroviruses
13.5.1.3.1.3. Alphaviruses
13.5.1.3.1.4. Adeno-
Associated Virus
13.5.1.3.1.5. Herpes
Simplex Virus
13.5.1.3.1.6. Vaccinia
Viruses
13.5.1.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
13.5.1.3.2. Non-Viral Vectors
13.5.1.3.2.1. Naked
DNA
13.5.1.3.2.2. Oligonucleotides
13.5.1.3.2.3. Lipoplexes
and Polyplexes
13.5.1.3.3. Human Artificial Chromosome
13.5.2. Japan
13.5.2.1. Japan Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.2.1.1. Germ Line Gene Therapy
13.5.2.1.2. Somatic Gene Therapy
13.5.2.1.2.1. Ex
Vivo Gene Therapy
13.5.2.1.2.2. In
Vivo Gene Therapy
13.5.2.2. Japan Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
13.5.2.2.1. Cancer
13.5.2.2.2. Infectious Diseases
13.5.2.2.3. Rheumatoid Arthritis
13.5.2.2.4. Genetic Disorders
13.5.2.2.5. Neurological Disorders
13.5.2.2.6. Others
13.5.2.3. Japan Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
13.5.2.3.1. Viral Vectors
13.5.2.3.1.1. Adenoviruses
13.5.2.3.1.2. Retroviruses
13.5.2.3.1.3. Alphaviruses
13.5.2.3.1.4. Adeno-
Associated Virus
13.5.2.3.1.5. Herpes
Simplex Virus
13.5.2.3.1.6. Vaccinia
Viruses
13.5.2.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
13.5.2.3.2. Non-Viral Vectors
13.5.2.3.2.1. Naked
DNA
13.5.2.3.2.2. Oligonucleotides
13.5.2.3.2.3. Lipoplexes
and Polyplexes
13.5.2.3.3. Human Artificial Chromosome
13.5.3. India
13.5.3.1. India Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.3.1.1. Germ Line Gene Therapy
13.5.3.1.2. Somatic Gene Therapy
13.5.3.1.2.1. Ex
Vivo Gene Therapy
13.5.3.1.2.2. In
Vivo Gene Therapy
13.5.3.2. India Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
13.5.3.2.1. Cancer
13.5.3.2.2. Infectious Diseases
13.5.3.2.3. Rheumatoid Arthritis
13.5.3.2.4. Genetic Disorders
13.5.3.2.5. Neurological Disorders
13.5.3.2.6. Others
13.5.3.3. India Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
13.5.3.3.1. Viral Vectors
13.5.3.3.1.1. Adenoviruses
13.5.3.3.1.2. Retroviruses
13.5.3.3.1.3. Alphaviruses
13.5.3.3.1.4. Adeno-
Associated Virus
13.5.3.3.1.5. Herpes
Simplex Virus
13.5.3.3.1.6. Vaccinia
Viruses
13.5.3.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
13.5.3.3.2. Non-Viral Vectors
13.5.3.3.2.1. Naked
DNA
13.5.3.3.2.2. Oligonucleotides
13.5.3.3.2.3. Lipoplexes
and Polyplexes
13.5.3.3.3. Human Artificial Chromosome
13.5.4. New
Zealand
13.5.4.1. New Zealand Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.4.1.1. Germ Line Gene Therapy
13.5.4.1.2. Somatic Gene Therapy
13.5.4.1.2.1. Ex
Vivo Gene Therapy
13.5.4.1.2.2. In
Vivo Gene Therapy
13.5.4.2. New Zealand Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Area
13.5.4.2.1. Cancer
13.5.4.2.2. Infectious Diseases
13.5.4.2.3. Rheumatoid Arthritis
13.5.4.2.4. Genetic Disorders
13.5.4.2.5. Neurological Disorders
13.5.4.2.6. Others
13.5.4.3. New Zealand Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Vector Type
13.5.4.3.1. Viral Vectors
13.5.4.3.1.1. Adenoviruses
13.5.4.3.1.2. Retroviruses
13.5.4.3.1.3. Alphaviruses
13.5.4.3.1.4. Adeno-
Associated Virus
13.5.4.3.1.5. Herpes
Simplex Virus
13.5.4.3.1.6. Vaccinia
Viruses
13.5.4.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
13.5.4.3.2. Non-Viral Vectors
13.5.4.3.2.1. Naked
DNA
13.5.4.3.2.2. Oligonucleotides
13.5.4.3.2.3. Lipoplexes
and Polyplexes
13.5.4.3.3. Human Artificial Chromosome
13.5.5. Australia
13.5.5.1. Australia Gene Therapy Market Revenue (US$ Mn) and Forecasts,
By Type
13.5.5.1.1. Germ Line Gene Therapy
13.5.5.1.2. Somatic Gene Therapy
13.5.5.1.2.1. Ex
Vivo Gene Therapy
13.5.5.1.2.2. In
Vivo Gene Therapy
13.5.5.2. Australia Gene Therapy Market Revenue (US$ Mn) and Forecasts,
By Therapy Area
13.5.5.2.1. Cancer
13.5.5.2.2. Infectious Diseases
13.5.5.2.3. Rheumatoid Arthritis
13.5.5.2.4. Genetic Disorders
13.5.5.2.5. Neurological Disorders
13.5.5.2.6. Others
13.5.5.3. Australia Gene Therapy Market Revenue (US$ Mn) and Forecasts,
By Vector Type
13.5.5.3.1. Viral Vectors
13.5.5.3.1.1. Adenoviruses
13.5.5.3.1.2. Retroviruses
13.5.5.3.1.3. Alphaviruses
13.5.5.3.1.4. Adeno-
Associated Virus
13.5.5.3.1.5. Herpes
Simplex Virus
13.5.5.3.1.6. Vaccinia
Viruses
13.5.5.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
13.5.5.3.2. Non-Viral Vectors
13.5.5.3.2.1. Naked
DNA
13.5.5.3.2.2. Oligonucleotides
13.5.5.3.2.3. Lipoplexes
and Polyplexes
13.5.5.3.3. Human Artificial Chromosome
13.5.6. South
Korea
13.5.6.1. South Korea Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.6.1.1. Germ Line Gene Therapy
13.5.6.1.2. Somatic Gene Therapy
13.5.6.1.2.1. Ex
Vivo Gene Therapy
13.5.6.1.2.2. In
Vivo Gene Therapy
13.5.6.2. South Korea Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Area
13.5.6.2.1. Cancer
13.5.6.2.2. Infectious Diseases
13.5.6.2.3. Rheumatoid Arthritis
13.5.6.2.4. Genetic Disorders
13.5.6.2.5. Neurological Disorders
13.5.6.2.6. Others
13.5.6.3. South Korea Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Vector Type
13.5.6.3.1. Viral Vectors
13.5.6.3.1.1. Adenoviruses
13.5.6.3.1.2. Retroviruses
13.5.6.3.1.3. Alphaviruses
13.5.6.3.1.4. Adeno-
Associated Virus
13.5.6.3.1.5. Herpes
Simplex Virus
13.5.6.3.1.6. Vaccinia
Viruses
13.5.6.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
13.5.6.3.2. Non-Viral Vectors
13.5.6.3.2.1. Naked
DNA
13.5.6.3.2.2. Oligonucleotides
13.5.6.3.2.3. Lipoplexes
and Polyplexes
13.5.6.3.3. Human Artificial Chromosome
13.5.7. Southeast
Asia
13.5.7.1. Southeast Asia Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.7.1.1. Germ Line Gene Therapy
13.5.7.1.2. Somatic Gene Therapy
13.5.7.1.2.1. Ex
Vivo Gene Therapy
13.5.7.1.2.2. In
Vivo Gene Therapy
13.5.7.2. Southeast Asia Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Area
13.5.7.2.1. Cancer
13.5.7.2.2. Infectious Diseases
13.5.7.2.3. Rheumatoid Arthritis
13.5.7.2.4. Genetic Disorders
13.5.7.2.5. Neurological Disorders
13.5.7.2.6. Others
13.5.7.3. Southeast Asia Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Vector Type
13.5.7.3.1. Viral Vectors
13.5.7.3.1.1. Adenoviruses
13.5.7.3.1.2. Retroviruses
13.5.7.3.1.3. Alphaviruses
13.5.7.3.1.4. Adeno-
Associated Virus
13.5.7.3.1.5. Herpes
Simplex Virus
13.5.7.3.1.6. Vaccinia
Viruses
13.5.7.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
13.5.7.3.2. Non-Viral Vectors
13.5.7.3.2.1. Naked
DNA
13.5.7.3.2.2. Oligonucleotides
13.5.7.3.2.3. Lipoplexes
and Polyplexes
13.5.7.3.3. Human Artificial Chromosome
13.5.7.4. Southeast Asia Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest of Asia Pacific Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.8.1.1. Germ Line Gene Therapy
13.5.8.1.2. Somatic Gene Therapy
13.5.8.1.2.1. Ex
Vivo Gene Therapy
13.5.8.1.2.2. In
Vivo Gene Therapy
13.5.8.2. Rest of Asia Pacific Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Area
13.5.8.2.1. Cancer
13.5.8.2.2. Infectious Diseases
13.5.8.2.3. Rheumatoid Arthritis
13.5.8.2.4. Genetic Disorders
13.5.8.2.5. Neurological Disorders
13.5.8.2.6. Others
13.5.8.3. Rest of Asia Pacific Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Vector Type
13.5.8.3.1. Viral Vectors
13.5.8.3.1.1. Adenoviruses
13.5.8.3.1.2. Retroviruses
13.5.8.3.1.3. Alphaviruses
13.5.8.3.1.4. Adeno-
Associated Virus
13.5.8.3.1.5. Herpes
Simplex Virus
13.5.8.3.1.6. Vaccinia
Viruses
13.5.8.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
13.5.8.3.2. Non-Viral Vectors
13.5.8.3.2.1. Naked
DNA
13.5.8.3.2.2. Oligonucleotides
13.5.8.3.2.3. Lipoplexes
and Polyplexes
13.5.8.3.3. Human Artificial Chromosome
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By Type
13.6.3. By
Therapy Area
13.6.4. By
Vector Type
14. Middle East and Africa Gene Therapy Market Analysis and
Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Middle
East and Africa Gene Therapy Market Revenue (US$ Mn)
14.2. Middle
East and Africa Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Germ
Line Gene Therapy
14.2.2. Somatic
Gene Therapy
14.2.2.1. Ex Vivo Gene Therapy
14.2.2.2. In Vivo Gene Therapy
14.3. Middle
East and Africa Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Area
14.3.1. Cancer
14.3.2. Infectious
Diseases
14.3.3. Rheumatoid
Arthritis
14.3.4. Genetic
Disorders
14.3.5. Neurological
Disorders
14.3.6. Others
14.4. Middle
East and Africa Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Vector Type
14.4.1. Viral
Vectors
14.4.1.1. Adenoviruses
14.4.1.2. Retroviruses
14.4.1.3. Alphaviruses
14.4.1.4. Adeno- Associated Virus
14.4.1.5. Herpes Simplex Virus
14.4.1.6. Vaccinia Viruses
14.4.1.7. Others (Lentivirus, Vaccinia Virus, Etc.)
14.4.2. Non-Viral
Vectors
14.4.2.1. Naked DNA
14.4.2.2. Oligonucleotides
14.4.2.3. Lipoplexes and Polyplexes
14.4.3. Human
Artificial Chromosome
14.5. Middle
East and Africa Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi Arabia Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Type
14.5.1.1.1. Germ Line Gene Therapy
14.5.1.1.2. Somatic Gene Therapy
14.5.1.1.2.1. Ex
Vivo Gene Therapy
14.5.1.1.2.2. In
Vivo Gene Therapy
14.5.1.2. Saudi Arabia Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Area
14.5.1.2.1. Cancer
14.5.1.2.2. Infectious Diseases
14.5.1.2.3. Rheumatoid Arthritis
14.5.1.2.4. Genetic Disorders
14.5.1.2.5. Neurological Disorders
14.5.1.2.6. Others
14.5.1.3. Saudi Arabia Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Vector Type
14.5.1.3.1. Viral Vectors
14.5.1.3.1.1. Adenoviruses
14.5.1.3.1.2. Retroviruses
14.5.1.3.1.3. Alphaviruses
14.5.1.3.1.4. Adeno-
Associated Virus
14.5.1.3.1.5. Herpes
Simplex Virus
14.5.1.3.1.6. Vaccinia
Viruses
14.5.1.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
14.5.1.3.2. Non-Viral Vectors
14.5.1.3.2.1. Naked
DNA
14.5.1.3.2.2. Oligonucleotides
14.5.1.3.2.3. Lipoplexes
and Polyplexes
14.5.1.3.3. Human Artificial Chromosome
14.5.2. UAE
14.5.2.1. UAE Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.2.1.1. Germ Line Gene Therapy
14.5.2.1.2. Somatic Gene Therapy
14.5.2.1.2.1. Ex
Vivo Gene Therapy
14.5.2.1.2.2. In
Vivo Gene Therapy
14.5.2.2. UAE Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
14.5.2.2.1. Cancer
14.5.2.2.2. Infectious Diseases
14.5.2.2.3. Rheumatoid Arthritis
14.5.2.2.4. Genetic Disorders
14.5.2.2.5. Neurological Disorders
14.5.2.2.6. Others
14.5.2.3. UAE Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
14.5.2.3.1. Viral Vectors
14.5.2.3.1.1. Adenoviruses
14.5.2.3.1.2. Retroviruses
14.5.2.3.1.3. Alphaviruses
14.5.2.3.1.4. Adeno-
Associated Virus
14.5.2.3.1.5. Herpes
Simplex Virus
14.5.2.3.1.6. Vaccinia
Viruses
14.5.2.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
14.5.2.3.2. Non-Viral Vectors
14.5.2.3.2.1. Naked
DNA
14.5.2.3.2.2. Oligonucleotides
14.5.2.3.2.3. Lipoplexes
and Polyplexes
14.5.2.3.3. Human Artificial Chromosome
14.5.3. Egypt
14.5.3.1. Egypt Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.3.1.1. Germ Line Gene Therapy
14.5.3.1.2. Somatic Gene Therapy
14.5.3.1.2.1. Ex
Vivo Gene Therapy
14.5.3.1.2.2. In
Vivo Gene Therapy
14.5.3.2. Egypt Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
14.5.3.2.1. Cancer
14.5.3.2.2. Infectious Diseases
14.5.3.2.3. Rheumatoid Arthritis
14.5.3.2.4. Genetic Disorders
14.5.3.2.5. Neurological Disorders
14.5.3.2.6. Others
14.5.3.3. Egypt Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
14.5.3.3.1. Viral Vectors
14.5.3.3.1.1. Adenoviruses
14.5.3.3.1.2. Retroviruses
14.5.3.3.1.3. Alphaviruses
14.5.3.3.1.4. Adeno-
Associated Virus
14.5.3.3.1.5. Herpes
Simplex Virus
14.5.3.3.1.6. Vaccinia
Viruses
14.5.3.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
14.5.3.3.2. Non-Viral Vectors
14.5.3.3.2.1. Naked
DNA
14.5.3.3.2.2. Oligonucleotides
14.5.3.3.2.3. Lipoplexes
and Polyplexes
14.5.3.3.3. Human Artificial Chromosome
14.5.4. Kuwait
14.5.4.1. Kuwait Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.4.1.1. Germ Line Gene Therapy
14.5.4.1.2. Somatic Gene Therapy
14.5.4.1.2.1. Ex
Vivo Gene Therapy
14.5.4.1.2.2. In
Vivo Gene Therapy
14.5.4.2. Kuwait Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
14.5.4.2.1. Cancer
14.5.4.2.2. Infectious Diseases
14.5.4.2.3. Rheumatoid Arthritis
14.5.4.2.4. Genetic Disorders
14.5.4.2.5. Neurological Disorders
14.5.4.2.6. Others
14.5.4.3. Kuwait Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
14.5.4.3.1. Viral Vectors
14.5.4.3.1.1. Adenoviruses
14.5.4.3.1.2. Retroviruses
14.5.4.3.1.3. Alphaviruses
14.5.4.3.1.4. Adeno-
Associated Virus
14.5.4.3.1.5. Herpes
Simplex Virus
14.5.4.3.1.6. Vaccinia
Viruses
14.5.4.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
14.5.4.3.2. Non-Viral Vectors
14.5.4.3.2.1. Naked
DNA
14.5.4.3.2.2. Oligonucleotides
14.5.4.3.2.3. Lipoplexes
and Polyplexes
14.5.4.3.3. Human Artificial Chromosome
14.5.5. South
Africa
14.5.5.1. South Africa Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Type
14.5.5.1.1. Germ Line Gene Therapy
14.5.5.1.2. Somatic Gene Therapy
14.5.5.1.2.1. Ex
Vivo Gene Therapy
14.5.5.1.2.2. In
Vivo Gene Therapy
14.5.5.2. South Africa Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Area
14.5.5.2.1. Cancer
14.5.5.2.2. Infectious Diseases
14.5.5.2.3. Rheumatoid Arthritis
14.5.5.2.4. Genetic Disorders
14.5.5.2.5. Neurological Disorders
14.5.5.2.6. Others
14.5.5.3. South Africa Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Vector Type
14.5.5.3.1. Viral Vectors
14.5.5.3.1.1. Adenoviruses
14.5.5.3.1.2. Retroviruses
14.5.5.3.1.3. Alphaviruses
14.5.5.3.1.4. Adeno-
Associated Virus
14.5.5.3.1.5. Herpes
Simplex Virus
14.5.5.3.1.6. Vaccinia
Viruses
14.5.5.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
14.5.5.3.2. Non-Viral Vectors
14.5.5.3.2.1. Naked
DNA
14.5.5.3.2.2. Oligonucleotides
14.5.5.3.2.3. Lipoplexes
and Polyplexes
14.5.5.3.3. Human Artificial Chromosome
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Gene Therapy Market Revenue
(US$ Mn) and Forecasts, By Type
14.5.6.1.1. Germ Line Gene Therapy
14.5.6.1.2. Somatic Gene Therapy
14.5.6.1.2.1. Ex
Vivo Gene Therapy
14.5.6.1.2.2. In
Vivo Gene Therapy
14.5.6.2. Rest of Middle East & Africa Gene Therapy Market Revenue
(US$ Mn) and Forecasts, By Therapy Area
14.5.6.2.1. Cancer
14.5.6.2.2. Infectious Diseases
14.5.6.2.3. Rheumatoid Arthritis
14.5.6.2.4. Genetic Disorders
14.5.6.2.5. Neurological Disorders
14.5.6.2.6. Others
14.5.6.3. Rest of Middle East & Africa Gene Therapy Market Revenue
(US$ Mn) and Forecasts, By Vector Type
14.5.6.3.1. Viral Vectors
14.5.6.3.1.1. Adenoviruses
14.5.6.3.1.2. Retroviruses
14.5.6.3.1.3. Alphaviruses
14.5.6.3.1.4. Adeno-
Associated Virus
14.5.6.3.1.5. Herpes
Simplex Virus
14.5.6.3.1.6. Vaccinia
Viruses
14.5.6.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
14.5.6.3.2. Non-Viral Vectors
14.5.6.3.2.1. Naked
DNA
14.5.6.3.2.2. Oligonucleotides
14.5.6.3.2.3. Lipoplexes
and Polyplexes
14.5.6.3.3. Human Artificial Chromosome
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By Type
14.6.3. By
Therapy Area
14.6.4. By
Vector Type
15. Latin America Gene Therapy Market Analysis and Forecasts,
2019 - 2027
15.1. Overview
15.1.1. Latin
America Gene Therapy Market Revenue (US$ Mn)
15.2. Latin
America Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Germ
Line Gene Therapy
15.2.2. Somatic
Gene Therapy
15.2.2.1. Ex Vivo Gene Therapy
15.2.2.2. In Vivo Gene Therapy
15.3. Latin
America Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy Area
15.3.1. Cancer
15.3.2. Infectious
Diseases
15.3.3. Rheumatoid
Arthritis
15.3.4. Genetic
Disorders
15.3.5. Neurological
Disorders
15.3.6. Others
15.4. Latin
America Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Vector Type
15.4.1. Viral
Vectors
15.4.1.1. Adenoviruses
15.4.1.2. Retroviruses
15.4.1.3. Alphaviruses
15.4.1.4. Adeno- Associated Virus
15.4.1.5. Herpes Simplex Virus
15.4.1.6. Vaccinia Viruses
15.4.1.7. Others (Lentivirus, Vaccinia Virus, Etc.)
15.4.2. Non-Viral
Vectors
15.4.2.1. Naked DNA
15.4.2.2. Oligonucleotides
15.4.2.3. Lipoplexes and Polyplexes
15.4.3. Human
Artificial Chromosome
15.5. Latin
America Gene Therapy Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Type
15.5.1.1.1. Germ Line Gene Therapy
15.5.1.1.2. Somatic Gene Therapy
15.5.1.1.2.1. Ex
Vivo Gene Therapy
15.5.1.1.2.2. In
Vivo Gene Therapy
15.5.1.2. Brazil Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Area
15.5.1.2.1. Cancer
15.5.1.2.2. Infectious Diseases
15.5.1.2.3. Rheumatoid Arthritis
15.5.1.2.4. Genetic Disorders
15.5.1.2.5. Neurological Disorders
15.5.1.2.6. Others
15.5.1.3. Brazil Gene Therapy Market Revenue (US$ Mn) and Forecasts, By
Vector Type
15.5.1.3.1. Viral Vectors
15.5.1.3.1.1. Adenoviruses
15.5.1.3.1.2. Retroviruses
15.5.1.3.1.3. Alphaviruses
15.5.1.3.1.4. Adeno-
Associated Virus
15.5.1.3.1.5. Herpes
Simplex Virus
15.5.1.3.1.6. Vaccinia
Viruses
15.5.1.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
15.5.1.3.2. Non-Viral Vectors
15.5.1.3.2.1. Naked
DNA
15.5.1.3.2.2. Oligonucleotides
15.5.1.3.2.3. Lipoplexes
and Polyplexes
15.5.1.3.3. Human Artificial Chromosome
15.5.2. Argentina
15.5.2.1. Argentina Gene Therapy Market Revenue (US$ Mn) and Forecasts,
By Type
15.5.2.1.1. Germ Line Gene Therapy
15.5.2.1.2. Somatic Gene Therapy
15.5.2.1.2.1. Ex
Vivo Gene Therapy
15.5.2.1.2.2. In
Vivo Gene Therapy
15.5.2.2. Argentina Gene Therapy Market Revenue (US$ Mn) and Forecasts,
By Therapy Area
15.5.2.2.1. Cancer
15.5.2.2.2. Infectious Diseases
15.5.2.2.3. Rheumatoid Arthritis
15.5.2.2.4. Genetic Disorders
15.5.2.2.5. Neurological Disorders
15.5.2.2.6. Others
15.5.2.3. Argentina Gene Therapy Market Revenue (US$ Mn) and Forecasts,
By Vector Type
15.5.2.3.1. Viral Vectors
15.5.2.3.1.1. Adenoviruses
15.5.2.3.1.2. Retroviruses
15.5.2.3.1.3. Alphaviruses
15.5.2.3.1.4. Adeno-
Associated Virus
15.5.2.3.1.5. Herpes
Simplex Virus
15.5.2.3.1.6. Vaccinia
Viruses
15.5.2.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
15.5.2.3.2. Non-Viral Vectors
15.5.2.3.2.1. Naked
DNA
15.5.2.3.2.2. Oligonucleotides
15.5.2.3.2.3. Lipoplexes
and Polyplexes
15.5.2.3.3. Human Artificial Chromosome
15.5.3. Rest of
Latin America
15.5.3.1. Rest of Latin America Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Type
15.5.3.1.1. Germ Line Gene Therapy
15.5.3.1.2. Somatic Gene Therapy
15.5.3.1.2.1. Ex
Vivo Gene Therapy
15.5.3.1.2.2. In
Vivo Gene Therapy
15.5.3.2. Rest of Latin America Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Area
15.5.3.2.1. Cancer
15.5.3.2.2. Infectious Diseases
15.5.3.2.3. Rheumatoid Arthritis
15.5.3.2.4. Genetic Disorders
15.5.3.2.5. Neurological Disorders
15.5.3.2.6. Others
15.5.3.3. Rest of Latin America Gene Therapy Market Revenue (US$ Mn) and
Forecasts, By Vector Type
15.5.3.3.1. Viral Vectors
15.5.3.3.1.1. Adenoviruses
15.5.3.3.1.2. Retroviruses
15.5.3.3.1.3. Alphaviruses
15.5.3.3.1.4. Adeno-
Associated Virus
15.5.3.3.1.5. Herpes
Simplex Virus
15.5.3.3.1.6. Vaccinia
Viruses
15.5.3.3.1.7. Others
(Lentivirus, Vaccinia Virus, Etc.)
15.5.3.3.2. Non-Viral Vectors
15.5.3.3.2.1. Naked
DNA
15.5.3.3.2.2. Oligonucleotides
15.5.3.3.2.3. Lipoplexes
and Polyplexes
15.5.3.3.3. Human Artificial Chromosome
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By Type
15.6.3. By
Therapy Area
15.6.4. By
Vector Type
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2018
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. Advanced
Cell and Gene Therapy, LLC
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Applied
Genetic Technologies Corporation (AGTC)
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. Audentes
Therapeutics, Inc.
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Benitec
Biopharma
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Biogen
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. bluebird
bio, Inc.
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Bristol -
Myers Squibb Delta Company Limited
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Chiesi
Farmaceutici S.p.A.
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Eurofins
Genomics
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Genenta
Science
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. Genzyme
Corporation
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Gilead
Sciences, Inc.
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business
Strategies
17.13. GlaxoSmithKline
PLC
17.13.1. Company
Details
17.13.2. Company
Overview
17.13.3. Product
Offerings
17.13.4. Key
Developments
17.13.5. Financial
Analysis
17.13.6. SWOT
Analysis
17.13.7. Business
Strategies
17.14. Human
Stem Cells Institute PJSC
17.14.1. Company
Details
17.14.2. Company
Overview
17.14.3. Product
Offerings
17.14.4. Key
Developments
17.14.5. Financial
Analysis
17.14.6. SWOT
Analysis
17.14.7. Business
Strategies
17.15. Novartis
AG
17.15.1. Company
Details
17.15.2. Company
Overview
17.15.3. Product
Offerings
17.15.4. Key
Developments
17.15.5. Financial
Analysis
17.15.6. SWOT
Analysis
17.15.7. Business
Strategies
17.16. Orchard
Therapeutics plc
17.16.1. Company
Details
17.16.2. Company
Overview
17.16.3. Product
Offerings
17.16.4. Key
Developments
17.16.5. Financial
Analysis
17.16.6. SWOT
Analysis
17.16.7. Business
Strategies
17.17. Pfizer
Inc.
17.17.1. Company
Details
17.17.2. Company
Overview
17.17.3. Product
Offerings
17.17.4. Key
Developments
17.17.5. Financial
Analysis
17.17.6. SWOT
Analysis
17.17.7. Business
Strategies
17.18. Sangamo
Therapeutics
17.18.1. Company
Details
17.18.2. Company
Overview
17.18.3. Product
Offerings
17.18.4. Key
Developments
17.18.5. Financial
Analysis
17.18.6. SWOT
Analysis
17.18.7. Business
Strategies
17.19. Spark
Therapeutics, Inc.
17.19.1. Company
Details
17.19.2. Company
Overview
17.19.3. Product
Offerings
17.19.4. Key
Developments
17.19.5. Financial
Analysis
17.19.6. SWOT
Analysis
17.19.7. Business
Strategies
17.20. Voyager
Therapeutics, Inc.
17.20.1. Company
Details
17.20.2. Company
Overview
17.20.3. Product
Offerings
17.20.4. Key
Developments
17.20.5. Financial
Analysis
17.20.6. SWOT
Analysis
17.20.7. Business
Strategies
18. Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.